EyePoint Pharma appoints Fred Hassan to board; directors Guyer, Adamis resign for Merck roles

EyePoint, Inc.

David Guyer and Anthony Adamis resigned from board effective Sept 3, 2024 due to full-time roles at Merck & Co.
Fred Hassan appointed to board; board size reduced from 9 to 8 members.
Hassan received option grant for 60,000 shares vesting over 3 years, annual cash retainer $45k.
Karen Zaderej and Stuart Duty join Compensation Committee (Zaderej as Chair); Hassan joins Governance Committee.
Company nearing first patient dosing in Phase 3 LUGANO trial of DURAVYU for wet AMD.

item 5.02 item 8.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Fred Hassan

Director

EYPT · EyePoint, Inc.

Effective: 2024-09-03
Filed: September 4, 2024, 7:59 PM ET

the Board, upon the recommendation of the Governance and Nominating Committee of the Board (the "Governance and Nominating Committee"), reduced the size of the Board from nine to eight members and appointed Fred Hassan to fill the remaining vacancy on the Board.

Departed

David R. Guyer

Director

EYPT · EyePoint, Inc.

Effective: 2024-09-03
Successor: Fred Hassan
Filed: September 4, 2024, 7:59 PM ET

On September 3, 2024, David R. Guyer, M.D. and Anthony P. Adamis, M.D. resigned from the Board of Directors (the "Board") of EyePoint Pharmaceuticals, Inc. (the "Company") and all committees thereof, effective immediately.

Departed

Anthony P. Adamis

Director

EYPT · EyePoint, Inc.

Effective: 2024-09-03
Successor: Fred Hassan
Filed: September 4, 2024, 7:59 PM ET

On September 3, 2024, David R. Guyer, M.D. and Anthony P. Adamis, M.D. resigned from the Board of Directors (the "Board") of EyePoint Pharmaceuticals, Inc. (the "Company") and all committees thereof, effective immediately.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Fred Hassan was appointed as Director at EyePoint, Inc..

Action: appointed
Role: Director

Exact text from the filing

the Board, upon the recommendation of the Governance and Nominating Committee of the Board (the "Governance and Nominating Committee"), reduced the size of the Board from nine to eight members and appointed Fred Hassan to fill the remaining vacancy on the Board.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

David R. Guyer resigned as Director at EyePoint, Inc..

Action: resigned
Role: Director

Exact text from the filing

On September 3, 2024, David R. Guyer, M.D. and Anthony P. Adamis, M.D. resigned from the Board of Directors (the "Board") of EyePoint Pharmaceuticals, Inc. (the "Company") and all committees thereof, effective immediately.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Anthony P. Adamis resigned as Director at EyePoint, Inc..

Action: resigned
Role: Director

Exact text from the filing

On September 3, 2024, David R. Guyer, M.D. and Anthony P. Adamis, M.D. resigned from the Board of Directors (the "Board") of EyePoint Pharmaceuticals, Inc. (the "Company") and all committees thereof, effective immediately.

View on SEC.gov

EyePoint, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-24-103097

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.